IL-17 mediates resistance to anti-VEGF therapy

@article{Maniati2013IL17MR,
  title={IL-17 mediates resistance to anti-VEGF therapy},
  author={Eleni Maniati and Thorsten Hagemann},
  journal={Nature Medicine},
  year={2013},
  volume={19},
  pages={1092-1094}
}
Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy. 
View on Nature
ncbi.nlm.nih.gov
25 Citations
Background Citations
9

25 Citations

Citation Type

Citation Type

A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer
TLDR
This phase I open‐label study evaluated the safety, pharmacokinetics and pharmacodynamics of TRC105 in patients with metastatic castration‐resistant prostate cancer (mCRPC).
The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis
TLDR
This review will look into IL-17 and summarise the current information and data on its role in the pathophysiology of cancer as well as its potential application in the overall management of the disease.
The therapeutic value of targeting inflammation in gastrointestinal cancers.
Melatonin and IL‐25 modulate apoptosis and angiogenesis mediators in metastatic (CF‐41) and non‐metastatic (CMT‐U229) canine mammary tumour cells
TLDR
This is the first study evaluating the potential use of melatonin and IL-25 in metastatic and non-metastatic canine mammary tumor cells and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
Efficacy of melatonin, IL‐25 and siIL‐17B in tumorigenesis‐associated properties of breast cancer cell lines
Vascular toxicity associated with anti-angiogenic drugs.
TLDR
Vascular toxicities associated with TKIs, especially VEGFi, are discussed, and an up-to-date overview on molecular mechanisms underlying V EGFi-induced vascular toxicity and cardiovascular sequelae is provided.
Expression of IL‐17A, E, and F and their receptors in human prostatic cancer: Comparison with benign prostatic hyperplasia
TLDR
There has been no systematic comparisons of expression of IL‐17A, E, F and their receptors, infiltration of inflammatory cells, and changes in structural cells in PCa and BPH.
Hypoxia and TGF-β1 lead to endostatin resistance by cooperatively increasing cancer stem cells in A549 transplantation tumors
TLDR
Increased TGF-β1 and strengthened hypoxia in A549 transplantation tumors, as a result of ES therapy, cooperatively increase proportion of CSCs that are involved in ES resistance which was revealed by failure of tumor volume repression after continuously treatment with ES for 12 days.
Compensatory angiogenesis and tumor refractoriness
TLDR
A discourse on major compensatory angiogenic pathways operating at cellular and molecular levels and their attributes with resistance to anti-angiogenic agents along with strategic opinions on future setting in targeting tumor angiogenesis is offered.
Interluekin-17A (IL17A).
...
1
2
3
...

References

SHOWING 1-10 OF 14 REFERENCES
An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
TLDR
It is indicated that IL-17 promotes tumor resistance to VEGF inhibition, suggesting that immunomodulatory strategies could improve the efficacy of anti-angiogenic therapy.
Macrophage regulation of tumor responses to anticancer therapies.
The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
TLDR
The biology of VEGF and its receptors, the use of anti-VEGF approaches in clinical disease, the toxicity of these therapies, and the resistance mechanisms that have limited the activity of these agents when used as monotherapy are reviewed.
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
TLDR
Findings indicate that, in models, refractoriness to anti-VEGF treatment is determined by the ability of tumors to prime and recruit CD11b+Gr1+ cells.
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.
Angiogenesis as a therapeutic target
TLDR
Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.
Molecular mechanisms and clinical applications of angiogenesis
TLDR
Preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
Cytokine networks in solid human tumors: regulation of angiogenesis
TLDR
The sites of production and multifaceted role of several key cytokines in the stimulation of a new blood supply within growing neoplasms are reviewed and the clinical implications and new therapeutic targets suggested are discussed.
The role of tumour–stromal interactions in modifying drug response: challenges and opportunities
TLDR
Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy, which can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
...
1
2
...